Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Overview

How likely is it that the drugs in Asthma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Asthma Overview

Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath.These may occur a few times a day or a few times per week. Depending on the person, asthma symptoms may become worse at night or with exercise. It is thought to be caused by a combination of genetic and environmental factors. Environmental factors include exposure to air pollution and allergens. Other potential triggers include medications such as aspirin and beta blockers. Diagnosis is usually based on the pattern of symptoms, response to therapy over time, and spirometry lung function testing.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Reasons to buy

  • Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
  • Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
  • Use PTSR and LOA information and event-driven changes for your investment decisions.

What our clients have to say

More Reports

View More Reports